Use of liquid chromatography–tandem mass spectrometry for the quantitative and qualitative analysis of an antipsychotic agent and its metabolites in human plasma and urine
- 1 January 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of Chromatography A
- Vol. 794 (1-2), 27-36
- https://doi.org/10.1016/s0021-9673(97)00688-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Preclinical Neurochemical and Electrophysiological Profile of 1192U90, A Potential AntipsychoticNeuropsychopharmacology, 1996
- New drugs for the treatment of schizophrenic patientsActa Psychiatrica Scandinavica, 1995
- The Evolution of the Serotonin-Dopamine Antagonist ConceptJournal of Clinical Psychopharmacology, 1995
- Serotonin, schizophrenia and antipsychotic drug actionSchizophrenia Research, 1995
- Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51w89 by liquid chromatography/mass spectrometryRapid Communications in Mass Spectrometry, 1995
- Depression in first-episode schizophreniaAmerican Journal of Psychiatry, 1993
- The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous systemPsychopharmacology, 1993
- Is schizophrenia a neurological disorder?The Journal of Neuropsychiatry and Clinical Neurosciences, 1992
- The current status of the dopamine hypothesis of schizophreniaNeuropsychopharmacology, 1988
- Positive vs. Negative Schizophrenia: A Critical EvaluationSchizophrenia Bulletin, 1985